Ann L. Oberg, Ph.D.

Location

Contact

SUMMARY

Ann L. Oberg, Ph.D., is a collaborative statistician with broad research experience in cell lines, xenografts, and retrospective and prospective human studies. She also has experience with various types of large-scale genomic data, such as mRNA expression, protein mass spectrometry, DNA sequencing and methylation. Dr. Oberg conducts research on disease mechanisms and markers of disease in ovarian cancer and on risk stratification and early detection in pancreatic cancer.

Focus areas

• Early detection of pancreatic cancer.
• Improving cancer risk stratification.
• Developing prognostic models of cancer risk.
• Experimental design and analysis strategies for patient-derived xenograft models.

Significance to patient care

Dr. Oberg's research initiatives are directed at finding markers of disease, disease risk or response to cancer treatment. These markers enable cancer to be detected earlier and allow patients to receive the best treatment for their situations. Dr. Oberg's work also helps improve understanding about how cancer develops and progresses so that treatments can be better tailored to individual patient characteristics.

Professional highlights

• Principle investigator, Management and Data Coordination Unit, Pancreatic Cancer Detection Consortium, National Cancer Institute, 2022-present.
• Alliance for Clinical Trials in Oncology:
  • Director, Computational Genomics and Bioinformatics Unit, 2017-present.
  • Associate group statistician, 2017-present.
• Director, Biostatistics and Bioinformatics Core, Ovarian Cancer SPORE, Mayo Clinic Comprehensive Cancer Center, 2008-present.